Introduction
The introduction of comprehensive vaccination programmes worldwide in 1950s has led to the global incidence of whooping cough (pertussis) falling dramatically (Roush et al., 2007) . Acellular vaccines (ACVs) containing purified pertussis antigens have replaced the traditional whole cell vaccines (WCVs) in most developed countries of the 45 world in the 1980s/1990s due to concerns over reactogenicity of WCVs (Greco et al., 1996) . All marketed pertussis ACVs contain detoxified pertussis toxin (PTd) with most containing varying doses of detoxified filamentous haemagglutinin (dFHA) and pertactin (d69K) or fimbrial antigens (Fim2&3). However, despite efficient vaccination programmes in many ACV covering countries, the incidence of pertussis is increasing 50 in both infants and vaccinated young adults with reported outbreaks in many countries including USA, Australia, Ireland and UK (Barret AS, June 2010 ; Nieves DJ, 2011; Spokes et al., 2010) . In addition, current understanding on the mechanism of vaccineinduced immunity, especially the role of T-cell and cell mediated immunity (CMI), and pertussis infection models indicate that altering the immune bias to a Th1/Th17 55 response is beneficial for clearance of bacteria (Dunne et al., 2010; Mahon et al., 1997) .
This suggests that improving the efficacy and durability of the protection induced by current ACVs is of importance and development of new generation of vaccines with long-lasting immunity is needed for better control of this disease. There are several possible explanations for the short duration of protection offered by ACVs, such as 60 incomplete antigen coverage and incorrect balance of antigens in the formulation. Most significantly, ACVs are widely acknowledged to be less protective than WCVs and require the inclusion of adjuvants that induce Th-1 cells to boost protective immunity.
The immune response in humans induced by current ACVs with aluminium as an adjuvant is predominantly Th-2 type response (Gupta and Ahsan, 2011; Leroux-Roels, Page 4 of 26 2010). However, despite that aluminium can effectively induce a strong antibody response, it is a weak adjuvant for the induction of CMI (Mahon et al., 1997) . The different profiles in cellular and humoral responses, macrophage activation and bacterial clearance of WCVs and ACVs indicated that different protective mechanisms are at work involving these two types of vaccine (Ausiello et al., 1997; Canthaboo et 70 al., 2002; Mills et al., 1998; Warfel et al., 2014) . Therefore, the development of a vaccine which can mount both cellular and humoral responses to generate a more effective and long lasting immune response would be the key to improve the efficacy of the current ACVs.
Biodegradable micro/nanoparticles (NP/MP) generated from poly(lactic-co-glycolic 75 acid) (PLGA) as a delivery system have attracted much attention due to their clinically proven biocompatibility and adjuvant activity during immunisation protocols (Danhier et al., 2012; Feczkó et al., 2011) . In particular, PLGA-based nano-and microparticles have been extensively investigated as a vaccine delivery system as well as used for controlled drug delivery for biopharmaceuticals (Abbas, 2008; Jiang et al., 2005; Kim 80 et al., 2016; Santillan et al., 2011) . Biodegradable particles with entrapped vaccine antigens, such as proteins, peptide or DNA, have recently been shown to possess significant potential as vaccine delivery systems. It is also known that size, charge and shape of particles play significant roles in antigen uptake. Both PLGA nanoparticles and microparticles have been investigated for vaccine delivery and demonstrated 85 significant differences in modulating immune responses (Gregory et al., 2013; Hiremath et al., 2016; Johansen et al., 2000; Peyre et al., 2004; Singh et al., 2015) . Nanopartilces are believed to promote cellular response whereas microparticles promote humoral one (Chong et al., 2005; Gutierro et al., 2002) . However, micropartilces with a size less than Page 5 of 26 Adjuvants function through three primary mechanisms: (1) protect and stabilise the entrapped antigen, (2) deliver antigen more effectively to antigen presenting cells (APCs), and (3) act as an immunostimulant adjuvant to activate or enhance immunity.
Particle-based antigen (Ag) delivery can potentially provide many levels of adjuvanticity that include: prolonging Ag residence in the body (depot formation); 95 enhancing Ag uptake mediated by dendritic cell (DC); direct stimulation of DC and promotion of cross-presentation especially in cases when new vaccine applications require cell-mediated immunity (Rice-Ficht et al., 2010) . Here we report a pilot study to investigate PLGA nano/micro particles as a candidate platform for the production of novel vaccines against pertussis that can enhance the efficacy of ACV. 100 PLGA micro/nanoparticles containing BSA was prepared using double emulsion (w/o/w) solvent evaporation method (Feczkó et al., 2011) . Briefly, appropriate amount of BSA (Table 1) Table 1 ) was added into the primary emulsion and was emulsified by sonicating at 37% for 3 minutes using the same sonicator under the same conditions to obtain the second emulsion. The organic solvent in the emulsion was evaporated under 125 magnetic stirring at 800 rpm for 2 hours in a fume cupboard under room temperature.
Materials and Methods

Materials
The obtained BSA-loaded PLGA particles were separated from the liquid medium by centrifugation (T1250 Sorvall Ultracentrifuge, Thermo Fisher Scientific, Inc. USA) at 25,000 rpm for 30 minutes. The isolated BAS-loaded PLGA particles were washed with deionised water and centrifuged again at 14,000 rpm for 15 minutes. The particles were 130 then washed with deionised water for two more times without centrifugation and were freeze-dried (Micromodulyo freeze dryer, Mecha Tech Systems, UK) for 19 hours. The final particles were stored in a freezer at -20ºC.
A range of BSA-loaded PLGA particle formulations were prepared by varying BSA loading ratio (% w/w BSA loading based on PLGA), PVA molecular weight, PVA 135 concentration in the aqueous phase and the phase ratio of the organic phase vs the second aqueous phase (Table 1) .
Preparation of final BSA-FTIC and pertussis toxoid-containing PLGA particles
The final PLGA particles containing BSA-FTIC and pertussis toxoid (PTd) for use in 140 the biological tests were prepared as described in Section 2.2.1. The BSA-FTIC orPTd loading ratio was 5 % (w/w); the PVA used has a molecular weight of 31,000 Da at a concentration of 1.75 % (w/v); and the phase ratio of the organic phase vs the second aqueous phase was 1:4.
Characterisation of antigen-loaded PLGA particles 145
Particle size and zeta potential measurement
Antigen (BSA-FTIC or PTd)-loaded PLGA particles (50 mg) were dispersed in 0.1% (w/v) PVA solution (molecular weight 31,000 Da). The particle size and zeta potential were determined using Zetasizer nanoseries (Malvern instruments, Malvern, UK) at 25ºC. When multiple peaks were present at the particle size measurement, the particle 150 size (mean ± SD) and percentage intensity of each peak were reported.
Surface morphology using scanning electron microscopy (SEM)
The surface morphologies of the antigen-loaded PLGA particles were examined using SEM (JEOL JSM-35 Scanning Microscope, JEOL (UK) Ltd, UK), with an electron energy at 5-10 keV. 155
Calculation of yield and encapsulation efficiency
The final weight of the antigen-loaded PLGA particles after freeze-drying was weighed and the yield (%) of the preparation was calculated using Equation 1.
Equation 1.
Yield (%)=Actual weight of the particles / The cortical weight of the particles*100%
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The encapsulation efficiency (%) was calculated using Equation 2.
Equation 2
Encapsulation efficiency (%) = Actual concentration of the antigen in the particles / The cortical concentration of the antigen in the particles*100%
Quantification of antigen loading 165
The antigen loading in the PLGA particles were quantified using BCA assay. The loaded particles (10 mg) were suspended in 1 ml 1M sodium hydroxide (NaOH) and agitated at 250 rpm using an electronic shaker for 3 hours at room temperature (RT) to hydrolyse the polymer. 3 ml of PBS (pH 7.4) and 1ml 1M hydrochloride acid (HCl) were added to the PLGA-NaOH mixture. The resultant sample (0.1ml) was mixed with 170 2 ml BCA reagent A and B (50:1). The absorbance of the above solution was measured using UV-Vis spectroscopy at 557 nm. Each measurement was repeated in triplication.
A calibration curve was prepared at BSA concentrations of 20, 40, 80, 120, 160 and 200 mg/ml.
Culture of J774.2 cells 175
Murine monocyte/macrophage J774.2 cells were maintained at 37°C under the presence of 5% CO2 in complete RPMI (cRPMI) comprising RPMI 1640 medium, 10% foetal calf serum, 10 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. soluble BSA-FITC were dispersed in cRPMI to prepare a 10mg/ml suspension . A 0.5 ml aliquot of the suspension was added to each well and incubated for 60 min at 37 o C, 185 in 5% CO2 whilst protected from light. The uptake was terminated by washing the cells twice with ice-cold PBS. The cells were then re-suspended in ice-cold PBS (1 ml) and centrifuged for 10 min at 118 g. The resultant pellet was re-suspended in 4 ml fixing solution (1% formaldehyde in PBS) and samples were stored at 4°C under protection from light. A FACS Canto II flow cytometer (BD Biosciences) was used to determine 190 the uptake of fluorescent particles.
Confocal laser-scanning microscopy
Two mililiter of 10 6 J774.2 cells in cRPMI was added to each well of a 24-well plated containing 0.2% gelatine (in PBS) coated sterile glass coverslips and incubated for 3h Following washing, to block non-specific binding, 300µl of blocking reagent (PBS-A containing 5% BSA ) was added to each well and incubated for 1 h at RT without shaking. Once washed, AlexaFluor594-conjugated phalloidin was used to stain the actin cytoskeleton for 5 min and subsequently 4,6-diamidino-2-phenylindole (DAPI) were applied for nuclear staining for 3 min. The fluorescent cells were visualised using 205 an NA 1.25 oil immersion lens on a laser-scanning confocal microscope (Leica SP2 AOBS) . Images were analysed using IMARIS software v7.4.2 (Bitplane, Switzerland).
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Immunisation of mice
The required doses of PTd NP/MP formulations were re-suspended in sterile PBS immediately prior to immunisation. Groups of 5 female NIH mice (6-8 week old, 210
Envigo, UK) were injected subcutaneously with 0.5 ml desired formulation at days 0 and 28. A further group of five mice were immunised with PBS as negative control.
Mice were sampled for sera at four weeks after primary immunisation and two weeks post-boost.
Antigen-specific serum IgG titres
215
Antibody response of the formulations was determined using antigen specific ELISA as described previously (Cheung et al., 2006) . Total antigen-specific IgG titres were determined relative to First International Reference Serum for pertussis (97/642, NIBSC, UK).
Protection studies by respiratory challenge
220
Two weeks after the second dose of immunisation, groups of 10 mice were subjected to aerosol challenge with a suspension of 10 8 cfu/ml B. pertussis 18.323 in 1% (w/v) casamino acids solution containing 0.6% w/v NaCl as described previously (Xing et al., 1999) . Successful infection was confirmed in 5 mice from the negative control group at 2 h post-infection. At 7 d post-infection, the lungs and trachea from remaining mice 225 were removed and homogenized in 1 ml casamino acids solution. Serial dilutions of the homogenate were plated onto charcoal agar (Oxoid) plates containing 10% (v/v) defibrinated horse blood (Oxoid) to perform viable counts. The numbers were expressed as CFU/lungs and trachea with a detection limit of 50 CFU/mouse. 
In vitro assays for cytokines from immune cells
Statistical analysis
240
Statistical analysis was performed using Combistat software Version 4.0, EDQM. Student's t-tests were performed to compare two groups with a. statistical significance defined as p<0.05.
Ethical approval
Ethical approval was obtained for all animal experiments from the Ethical Committee 245 of National Institute for Biological Standards and Control, UK. All experiments were regulated according to the Animal Scientific Procedures Act (1986), UK.
Results
Charateristics of antigen-loaded PLGA particles
250
The yield and encapsulation efficiency of BSA-containing PLGA particles produced during the formulation development are shown in Table 1 . F9 has achieved the highest yield, antigen loading, and encapsulation efficiency and was selected as the formulation Page 12 of 26 to produce the final BSA-FTIC and PTd loaded PLGA particles. The characteristics of the final BSA-FTIC and PTd loaded PLGA particles are shown in Table 2 . The 255 obtained antigen-loaded PLGA particles are a mixture of nanoparticles and microparticles exhibiting particle sizes in two size ranges (Table 2 ). Fig. 1 shows that the BSA-loaded PLGA particles are spherical with smooth surfaces.
Antigen phagocytosis by J774.2 cells
FITC-BSA was used as a model antigen to investigate NP/MP uptake by both 260
Fluorescence-activated cell sorting (FACS) and confocal microscopy. J774.2 murine macrophages were incubated with 120ug/ml FITC-BSA in soluble or particle formulation for 3h and 24h for analysis by confocal microscopy and FACS respectively. Fig.2 A-C shows the uptake of fluorescent antigen using confocal laserscanning microscopy quantified by flow cytometry (panels D-E). (Fig. 2B) . In contrast, punctate regions of green fluorescence were displayed in cells treated with NP/MP formulation suggesting enhanced FITC-BSA uptake by macrophages (Fig.2 C) . These observations were confirmed by flow cytometry. The cells that were exposed to BSA-FITC NP/MPs 270 exhibited enhanced phagocytosis with an increase in both the number of fluorescent cells and fluorescence intensity (Fig. 2D and 2E) , showing an increase in MedFI of the P2-gated population (Fig.2E) .
Antibody responses
Subcutaneous injection of mice with PTd encapsulated NP/MP formulation induced 275 similar or slightly lower anti-PT IgG titres compared with the soluble antigen at equivalent dose at both 28 and 42 d (Fig.3) . Immunisation with both the soluble and the NP/MP formulations gave good booster response which indicates memory response.
However, neither the antigen-specific IgG titres nor the duration of antibody response were altered by the NP/MP formulation indicating that it did not have adjuvant effect on 280 PT antibody responses in vivo.
Antigen-specific cytokine profile
To investigate the type of cytokine produced in the spleen cell supernatants, mice were 
Protective effect of PTd NP/MP formulation in an aerosol infection model
The protective effect of PTd NP/MP formulation against the infection was investigated in an aerosol challenge model. Under the current immunisation dose, an approximately 300 Page 14 of 26 10% reduction in CFU was found in the soluble PTd group in comparison to PBS control group. PTd in NP/MP formulation group showed similar results with a further ~5% reduction in CFU although this did not reach statistical significance (Fig.5) between these two groups.
305
Discussion
In the last two decades, pertussis has resurged in different countries. In particular significant mortality in infants were caused by large outbreaks in US, Australia, UK and The Netherlands in the 2010-2013 period, (Black RE, 2010; Cherry, 2010) . The epidemiological situation of pertussis is possibly to be related to suboptimal or waning 310 immunity induced by ACV (Klein et al., 2012) . This points out the urgent need to design and develop new vaccine formulation with high effectiveness in conferring protective immunity. In this study, we used biodegradable polymers as vaccine carriers to explore their ability to promote both Th1 and Th-17 cells immune responses for
pertussis. 315
The yield and encapsulation efficiency of the PLGA particles are extremely important for incorporating valuable protein antigens such as pertussis toxoid (PTd), and the capacity of antigen loading determines the volume of the final vaccine product.
Formulation parameters, including PVA molecular weight, PVA concentration and the phase ratio, were found to affect the loading capacity, yield and encapsulation 320 efficiency of the final particles using the double emulsion solvent evaporation method, in agreement with published studies (Bilati et al., 2005; Feczkó et al., 2011 ). The optimised formulation was able to successfully incorporate PTd with high loading, yield and encapsulation efficiency. The PTd-loaded PLGA particles showed dual-sized Page 15 of 26 characteristics, as a mixture of nanoparticles (size range 200-300 nm) and 325 microparticles (size ~5 µm). Both PLGA nanoparticles and microparticles as vaccine delivery have been reported to show differences in modulating cellular or humoral immune responses (Gutierro, Hernández et al. 2002 , Chong, Cao et al. 2005 , Champion, Walker et al. 2008 ). An in vitro study demonstrated that PLGA microparticles (5-7 µm) were attached to cell membrane and required more time to be engulfed by the 330 macrophages compared to nano-sized particles, which led to more potent inflammatory stimulus after the uptake process (Nicolete et al., 2011) . Therefore, it is difficult to predict the immune response by using either micro-or nanoparticles of PLGA as antigen carriers. In this pilot study, the combination of nanoparticles and microparticles were applied for in vitro and in vivo investigations to demonstrate the potential of 335 PLGA based particles for enhanced PTd delivery. Further separation of the particle sizes and investigation into their distinct effects will be the subject of future research.
Humoral immunity was shown to be critical for optimum protection against B. pertussis infection together with cell-mediated immunity; long term immunity is effectively maintained bymemory T and B cells and the highest level of protection is associated 340 with the Th1 subtype (Mills et al., 1998) . Antigens entrapped PLGA particles, when delivered parenterally,was found to stimulate cell-mediated immune responses (Moore et al., 1995) and PTd with another pertussis antigen FHA entrapped in biodegradable polymer particles have been reported to elicit a potent type 1 T cell and antibody response (Conway et al., 2001) . In the present study, INF-γ level from mice immunized 345
with PTd NP/MP were greatly enhanced. The MP/NP incorporated antigen showed ability to shift the T cell response from Th2 or mixed Th1/Th2 to Th1, which is consistent with above literature reports. This is further supported by the uptake and presentation of particulate antigen by phagocytic cellswhich are thought to act as antigen presenting cells (APC) for Th1 response (Gajewski TF, 1991) . In deed, great 350 enhancement of phagocytosis for NP/MP formulation by macrophages was observed in this study and this was in agreement with previous reports that INF-γ producing cells could activate macrophages to kill intracellular bacteria and thus play a critical role in protection against B. pertussis during primary infection (Barbic et al., 1997; Mahon et al., 1997) 355 While NP/MP formulations were found to have an effect on INF-γ producing cells, to our knowledge, effect of PTd NP/MP on Th17 cells has not been addressed so far. It was in recent years that the important role of Th17 cells in clearing pathogens during host defense reactions have attracted much attention (Korn et al., 2009) . In a nonhuman primates study, it was found that ACV vaccinated animals exhibited a Th1/Th2 360 response; however, previously infected animals and animals that were vaccinated using conventional whole cell pertussis possess strong B. pertussis-specific T helper 17 (Th17) memory as well as Th1 memory (Warfel et al., 2014) . Th17 cells were also reported to be involved in adaptive immunity to other pathogens e.g. Pseudomonas aeruginosa, Staphylococcus aureus (Lin et al., 2009; Priebe et al., 2008) . Here we 365 demonstrate that IL-17 secretion was significantly enhanced in the spleen cell culture from mice immunized with PTd NP/MP formulation which indicate that the NP/MP formulations were able to have enhancement effect on INF-γ as well as IL-17 producing cells. According to previous report, IL-17, especially IL-17A, and IFN-γ can promote macrophage killing of B. pertussis (Ross et al., 2013; Sarah C. Higgins, 2006) . 370
It has been reported that immunity of children who had received 5 doses of ACV wanes substantially each year (Klein et al., 2012) . Biodegradable NP/MP could have potential to avoid this problem by providing controlled antigen release from the Page 17 of 26 micro/nanoparticles which is resultant by efficient phagocytosis and transportation to the lymph nodes (Gray and Skarvall, 1988) . 375
In conclusion, these preliminary results suggested that NP/MP formulation could promote protective immunity both Th1 and Th-17 responses of pertussis antigen, which may enhance vaccine protective efficacy. NP/MP could be a potential candidate platform for the development of novel vaccines against pertussis. 
